Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The attachment inhibitor performed well as an adjunct to an optimized antiretroviral regimen among those with multidrug-resistant HIV.
New forms of treatment and PrEP and, hopefully, an at least partially effective vaccine will be key to fighting the epidemic in the 2020s.
The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.
Researchers attribute the decline in multidrug-resistant virus, which began in 2004, to newer, highly potent antiretrovirals.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
However, a recent literature review did not find a link between such exercise and improved inflammation.
Researchers have identified biomarkers that can identify NAFLD and rule out advanced fibrosis.
The PopART study is one of three that have recently reported findings of such programs in sub-Saharan Africa.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Updating previous, similar findings, researchers have now reported on 96-week data from a pair of ongoing trials.
A late-stage trial randomized people taking a stable HIV regimen to switch to Dovato or stay on their current antiretrovirals.
The World Health Organization recommends this highly effective antiretroviral for all population groups, including young women.
Large European study finds that more than 1 in 10 people with HIV acquire HCV again.
On-demand, or 2-1-1, PrEP requires taking only four doses of Truvada during the days surrounding sex.
A recent study randomized those with a moderate long-term risk of heart attack to receive Crestor (rosuvastatin) or a placebo.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.